© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Longeveron Inc. (LGVN) stock declined over -59.43%, trading at $2.71 on NASDAQ, down from the previous close of $6.68. The stock opened at $3.14, fluctuating between $2.70 and $3.35 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | 3.14 | 3.35 | 2.70 | 2.71 | 1.43M |
| Sep 16, 2026 | 6.83 | 7.15 | 6.52 | 6.68 | 28.63K |
| Sep 15, 2026 | 6.89 | 7.10 | 6.65 | 6.86 | 44.16K |
| Sep 14, 2026 | 7.36 | 7.60 | 6.92 | 6.92 | 61.77K |
| Sep 11, 2026 | 6.79 | 7.36 | 6.64 | 7.33 | 67.71K |
| Sep 10, 2026 | 6.52 | 6.80 | 6.50 | 6.64 | 59.55K |
| Sep 09, 2026 | 6.58 | 6.75 | 6.51 | 6.58 | 29.44K |
| Sep 08, 2026 | 6.78 | 6.90 | 6.56 | 6.65 | 50.13K |
| Sep 04, 2026 | 6.54 | 6.88 | 6.53 | 6.81 | 40.35K |
| Sep 03, 2026 | 6.82 | 7.04 | 6.55 | 6.58 | 43.91K |
| Sep 02, 2026 | 6.67 | 6.95 | 6.65 | 6.78 | 36.04K |
| Sep 01, 2026 | 6.86 | 7.05 | 6.61 | 6.75 | 32.52K |
| Aug 31, 2026 | 6.75 | 7.30 | 6.51 | 6.90 | 104.88K |
| Aug 28, 2026 | 6.80 | 7.25 | 6.55 | 6.72 | 79.68K |
| Aug 27, 2026 | 7.06 | 7.28 | 6.59 | 6.80 | 130.18K |
| Aug 26, 2026 | 6.86 | 7.40 | 6.76 | 7.03 | 65.83K |
| Aug 25, 2026 | 7.30 | 7.35 | 6.50 | 6.80 | 158.78K |
| Aug 24, 2026 | 8.50 | 8.70 | 8.05 | 8.38 | 81.19K |
| Aug 21, 2026 | 8.60 | 8.70 | 8.23 | 8.45 | 76.86K |
| Aug 20, 2026 | 8.40 | 8.90 | 8.18 | 8.28 | 61.68K |
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
| Employees | 38 |
| Beta | -0.26 |
| Sales or Revenue | $709.00K |
| 5Y Sales Change% | -0.757% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |